Medication Abortion

COX-2 inhibitor demonstrates potential in increasing efficacy of OTC LNG-EC pills; updated systematic review and meta-analysis supporting the effectiveness and safety of misoprostol-alone for medication abortion; support needs of adolescents and young adult abortion seekers; and more!

Continued support for misoprostol-only regimens for medication abortion and self-managed abortion between nine and 16 weeks gestation, the use of home pregnancy tests for follow-up care after a telehealth medication abortion, where adolescents and young adults go online to get abortion information, and disparities in recommended retesting for women with trichomonas vaginalis infections.

Men’s willingness to use novel birth control, characteristics of patients seeking telehealth medication abortion care, mifepristone as a potential treatment for adenomyosis, and the impact of the pill on adolescent bone health.

Providers are a critical link for abortion seekers.

Initial reports from the ongoing narrative collection Care Post Roe documenting poor-quality care, patient perspectives on telehealth medication abortion, adolescent preferences and experiences with pregnancy options counseling, and more.

Perceived pain and sedation dosing during abortion procedures by demographics, PAPP-A as a novel screening for gestational age before medication abortion, patient experiences with progestin-only pills and attitudes towards OTC access.

Dispelling misinformation about EC with your patients.